FDA approves Pfizer’s COVID-19 vaccine

The+US+Food+and+Drug+Association+gave+full+approval+to+the+Pfizer-BioNTech+COVID-19+vaccine+on+Monday+for+individuals+older+than+sixteen+years.+Previously%2C+the+treatment+was+only+administered+under+an+emergency+use+authorization+%28EUA%29%2C+which+was+granted+in+December+2020.

Arely Sun

The US Food and Drug Association gave full approval to the Pfizer-BioNTech COVID-19 vaccine on Monday for individuals older than sixteen years. Previously, the treatment was only administered under an emergency use authorization (EUA), which was granted in December 2020.

by Sabrina Zhu, STEM Editor

The US Food and Drug Association gave full approval to the Pfizer-BioNTech COVID-19 vaccine on Monday for individuals older than sixteen years. Previously, the treatment was only administered under an emergency use authorization (EUA), which was granted in December 2020.

Now, the technology within the two-dose vaccine will be known as Comirnaty and as a treatment that can prevent COVID-19. Those between twelve and fifteen years of age and those with weaker immune systems who require three doses can still receive the vaccine under the EUA.

The Pfizer vaccine is up to 92% effective against the delta variant, which is twice as contagious as other coronavirus strains. This variant has caused more severe symptoms in patients and a larger population feeling safe about receiving a vaccine could reduce circulation.

“I think [FDA approving the vaccine] is a good idea because there’s the delta variant now, it could be a little safer and could probably help with the likelihood of the virus spreading,” Claire Bauschlicher (10) said.

The FDA only grants full approval for treatments that have been researched for at least six months, instead of the two months required for emergency approval. During this period, over tens of thousands of people were studied, and the FDA carefully analyzed potential symptoms as well as the production process of the vaccine. 

“Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in the FDA press release. “We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes.”

Following the FDA’s decision, many schools and companies have announced that they will require all members to receive the vaccine. Additionally, the approval could comfort and inform citizens who were unsure about the Pfizer vaccine’s novel technology.

“I hope it will help people feel safer about getting the vaccine,” Makayla Aguilar (11) said. “I feel like before people were a little hesitant to get it.”